XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Net sales $ 3,909.5 $ 4,105.4 $ 7,628.6 $ 8,283.6
Biocon Biologics        
Disaggregation of Revenue [Line Items]        
Net sales   (161.8)   (326.6)
Brands        
Disaggregation of Revenue [Line Items]        
Net sales 2,444.7 2,483.1 4,865.0 5,037.2
Complex GX and Biosimilars        
Disaggregation of Revenue [Line Items]        
Net sales 139.2 354.8 275.3 745.6
Generics        
Disaggregation of Revenue [Line Items]        
Net sales 1,325.6 1,267.5 2,488.3 2,500.8
Lipitor        
Disaggregation of Revenue [Line Items]        
Net sales 380.0 405.6 797.9 845.7
Norvasc        
Disaggregation of Revenue [Line Items]        
Net sales 182.4 203.0 385.1 410.8
Lyrica ®        
Disaggregation of Revenue [Line Items]        
Net sales 137.1 155.8 281.4 327.4
Viagra ®        
Disaggregation of Revenue [Line Items]        
Net sales 111.0 115.1 226.0 244.9
EpiPen® Auto-Injectors        
Disaggregation of Revenue [Line Items]        
Net sales 127.5 106.5 223.3 195.3
Celebrex ®        
Disaggregation of Revenue [Line Items]        
Net sales 82.0 85.9 170.8 171.2
Effexor ®        
Disaggregation of Revenue [Line Items]        
Net sales 64.8 73.7 129.4 151.2
Zoloft ®        
Disaggregation of Revenue [Line Items]        
Net sales 54.5 62.5 111.0 135.6
Creon ®        
Disaggregation of Revenue [Line Items]        
Net sales 74.1 75.4 146.8 150.1
Xalabrands        
Disaggregation of Revenue [Line Items]        
Net sales 50.4 42.7 97.1 95.7
Amitiza ®        
Disaggregation of Revenue [Line Items]        
Net sales 41.5 44.1 78.1 85.9
Xanax ®        
Disaggregation of Revenue [Line Items]        
Net sales 51.8 37.2 91.5 77.2
Dymista ®        
Disaggregation of Revenue [Line Items]        
Net sales 57.7 55.5 110.9 99.4
Yupelri ®        
Disaggregation of Revenue [Line Items]        
Net sales 55.0 49.1 102.0 92.7
Developed Markets (1) | Brands        
Disaggregation of Revenue [Line Items]        
Net sales 1,300.2 1,305.4 2,532.2 2,604.1
Developed Markets (1) | Complex GX and Biosimilars        
Disaggregation of Revenue [Line Items]        
Net sales 132.7 327.0 262.6 691.1
Developed Markets (1) | Generics        
Disaggregation of Revenue [Line Items]        
Net sales 920.9 846.7 1,729.4 1,660.0
Greater China | Brands        
Disaggregation of Revenue [Line Items]        
Net sales 530.5 546.3 1,092.9 1,116.0
Greater China | Complex GX and Biosimilars        
Disaggregation of Revenue [Line Items]        
Net sales 0.0 0.3 0.0 0.3
Greater China | Generics        
Disaggregation of Revenue [Line Items]        
Net sales 1.6 1.7 3.8 5.1
JANZ | Brands        
Disaggregation of Revenue [Line Items]        
Net sales 207.4 243.1 397.7 492.1
JANZ | Complex GX and Biosimilars        
Disaggregation of Revenue [Line Items]        
Net sales 6.5 12.1 12.6 22.4
JANZ | Generics        
Disaggregation of Revenue [Line Items]        
Net sales 161.6 171.9 307.4 336.4
Emerging Markets Segment | Brands        
Disaggregation of Revenue [Line Items]        
Net sales 406.6 388.3 842.2 825.0
Emerging Markets Segment | Complex GX and Biosimilars        
Disaggregation of Revenue [Line Items]        
Net sales 0.0 15.4 0.1 31.8
Emerging Markets Segment | Generics        
Disaggregation of Revenue [Line Items]        
Net sales 241.5 247.2 447.7 499.3
Operating Segment | Developed Markets (1)        
Disaggregation of Revenue [Line Items]        
Net sales 2,353.8 2,479.1 4,524.2 4,955.2
Operating Segment | Greater China        
Disaggregation of Revenue [Line Items]        
Net sales 532.1 548.3 1,096.7 1,121.4
Operating Segment | JANZ        
Disaggregation of Revenue [Line Items]        
Net sales 375.5 427.1 717.7 850.9
Operating Segment | Emerging Markets Segment        
Disaggregation of Revenue [Line Items]        
Net sales $ 648.1 $ 650.9 $ 1,290.0 $ 1,356.1